Kamada

KMDA · NASDAQ

$7.85+$0.24 (+3.15%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $7.61

KMDA analyst rating

BuyConsensus of 1 analyst over the last 12 months. 100% rate it a buy.

Strong buy0
Buy1
Hold0
Underperform0
Sell0

12-month price target · 6 analysts

Average $13.77 (+75.4% upside)

Low: $11.11
Now: $7.85
High: $15.75

Upgrades and downgrades

The latest rating actions, newest first

KMDA analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
HC Wainwright & Co.	Dec 9, 2025	Maintains	Buy	$11.00 → $13.00	54%

The case for and against

Updated Oct 31, 2025

Bull case

Kamada Ltd is projected to generate revenues of $43.5 million in 2Q25, reflecting a 7% annual increase, alongside a slight rise in earnings per share from $0.07 to $0.08. The anticipated revenue growth is underpinned by a robust 19% increase in proprietary product sales during 1Q25, particularly from Glassia and Kamrab, as well as contributions from royalty income and additional product shipments under a significant contract in Latin America. Continued momentum from proprietary products in the U.S., new biosimilars in Israel, and expanding distribution channels are expected to sustain positive financial performance through the remainder of the year.

Bear case

Kamada Ltd has faced challenges in generating consistent revenue growth, primarily due to its heavy reliance on the Proprietary Products segment, which encounters competition and pricing pressures in the specialty therapeutics market. Additionally, the company has reported fluctuating profit margins and rising operational costs associated with research and development, further impacting its overall profitability. The dependency on a limited product portfolio, combined with potential regulatory hurdles and market dynamics, raises concerns about the sustainability of its financial performance moving forward.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.